# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Company aligned with FDA on key CMC topicsTonix also has completed the second and final pre-New Drug Application (NDA) meeting ...
Treatment with Tonmya™ (TNX-102 SL, sublingual cyclobenzaprine HCl) in Phase 3 RESILIENT study significantly reduced daily pain...
The public offering included 1,199,448 shares of common stock and pre-funded warrants to purchase up to 2,568,110 shares of com...